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included in the national Dutch influenza vaccination pro-
gram, that encompasses the elderly of 65 years and older.
The objective of this study is to estimate the cost and ben-
efits of vaccinating healthy working adults aged 25 to 64
years against influenza.
METHODS: Our cost-benefit analysis includes the direct
and indirect costs associated with vaccination as well as
the direct and indirect costs avoided by vaccination. The
underlying model links influenza incidence to health-care
resource use, work absenteeism and productivity loss.
Health-care resource use was specified for general practi-
tioner visits, hospitalizations and drugs. Clinical and eco-
nomical parameter estimates were derived from pub-
lished literature and Dutch registry data.
RESULTS: Vaccinating healthy working adults aged 25
to 44 years costs € 0,39 per person per year. Vaccinating
persons aged 45 to 64 years saves € 1,51 per person per
year. On the population level, vaccinating persons aged
25–44 years costs about € 1,4 million per year, vaccinat-
ing persons aged 45-64 years saves about € 2,3 million
per year. On average, vaccinating healthy working adults
saves € 0,9 million. The indirect costs prevented prima-
rily determine the cost-benefit outcome of vaccination for
healthy working adults.
CONCLUSIONS: Influenza vaccination of healthy work-
ing adults is cost saving. These findings support routine
vaccination for this group, from the employer’s perspective.
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OBJECTIVES: Toenail onychomycosis is the most com-
mon nail fungal infection. If left untreated, it can evolve
into a more severe stage that can involve the matrix. The
clinical management of patients remains constraining and
long. In addition, relapses occur frequently after antifun-
gal treatment. This has significant socio-economic im-
pact. Combining topical and oral antifungals can increase
cure rates and decrease treatment duration. The Ony-
choTree project aims at providing an evaluation tool to
estimate economic consequences of the management of
severe toenail onychomycosis in Europe.
METHODS: The methodology for OnychoTree develop-
ment follows a rigorous stepwise design to obtain an inter-
national model, valid for use across 17 countries: 1) an ex-
tensive literature review of international data on toenail
onychomycosis; 2) the design of a core clinical manage-
ment-decision tree; 3) the validation and completion of the
core model (treatment patterns and medical resource use)
by an expert panel of 12 dermatologists from six countries;
4) expansion and validation of the model to 11 additional
countries through advisory panel interviews assessing na-
tional specificities (disease management and associated
costs); 5) a meta-analysis of efficacy rates from relevant
clinical trials of antifungals; 6) cost-effectiveness analyses.
RESULTS: The initial common model was designed from
the available international literature. The expert panel
clinicians confirmed their interest for: 1) a clinical man-
agement model, and 2) cost-effectiveness evaluation in-
cluding new combination therapies. They requested ad-
aptations to reflect country-specific medical practice.
After adaptation, they validated the core European phar-
macoeconomic model. Advisory panel interviews con-
firmed these results, focusing on the need for country-
specific analyses based on a common decision tree.
CONCLUSIONS: Cost-effectiveness analyses including
the 17 country-specific data will be performed with the
final model. These European results will make both med-
ical professionals and the public aware of the possible im-
provement in health-care resource use for the manage-
ment of severe toenail onychomycosis.
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OBJECTIVE: We conducted a cost-benefit analysis of
two approaches to manage a regional outbreak of sero-
group C meningococcal disease (MCD): 1. a planned
mass immunization program (MIP) of 2,000,000 Quebec
residents aged 2 months to 20 years, that would be im-
plemented in September 2001; 2. an emergency MIP im-
plemented at the peak of subsequent outbreaks.
METHODS: As a reference case, we used the scenario
that occurred in Quebec in 1991—several targeted re-
gional vaccination programs were implemented in an at-
tempt to ward off a more widespread outbreak of MCD.
Unfortunately, at the end of 1992, public-health authori-
ties had to implement a province-wide emergency MIP.
We assessed the benefit of the programs using epidemio-
logical data from the previous cycle of MCD in Quebec.
Benefits included the number of new MCD cases pre-
vented by the administration of Menjugate™ and their
associated hospital and societal costs due to premature
mortality and related morbidity. Costs included acquisi-
tion and administration cost of the conjugate vaccine,
clerical, physician and health-services costs, and those re-
lated to lost productivity. We conducted the analysis in a
societal perspective assuming Quebec would face a simi-
lar epidemiological situation in 2001 as the one that
started in 1991. All costs were transformed into 2001
Canadian dollars at an annual inflation rate of 3%.
RESULTS: Over a 12-month period, a planned MIP
would prevent 127 new cases (18 deaths, 24 major com-
plications) while saving $15.0 million in direct costs to
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the Ministry of Health and $19.8 million in societal costs
to the province of Quebec.
CONCLUSION: As Quebec is facing a new epidemic cy-
cle of MCD, the results of this analysis suggest that a
planned MIP to be implemented in September 2001,
would be cost-beneficial as opposed to delaying mass im-
munization until another outbreak occurs.
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OBJECTIVE: This study aims to determine the burden of
illness of severe sepsis (a systemic response to infection in
critically ill patients that often leads to death) in Ger-
many by calculating the direct and indirect patient-
related costs for patients with severe sepsis.
METHODS: Direct ICU costs were determined by a bot-
tom up approach, retrospectively evaluating 385 elec-
tronic records of patients with severe sepsis from three
adult intensive-care units in three university hospitals in
Germany for resource use (medication, laboratory tests,
microbiological analyses, disposables, and clinical proce-
dures), linking the findings with assessed centre-specific
unit costs and adding centre-specific personnel and basic
bed (“hotel”) costs. Indirect costs of illness, those result-
ing from unfitness for work, early retirement, and prema-
ture death, were calculated according to the human capi-
tal approach, using official German statistics.
RESULTS: The mean direct ICU cost of care was € 25,696
per patient. The combination of the incidence range
(45,000–94,000 severe sepsis cases per year in Germany)
with these mean total direct costs yielded a direct cost
range from € 1,130 Mio to € 2,440 Mio for severe sepsis
in Germany. The productivity loss due to temporary
morbidity counts was € 151–326 Mio. Productivity loss
due to permanent morbidity amounts to € 638 to 1,377
Mio and the loss due to premature death is € 3,275 to
7,071 Mio. Direct and indirect costs add up to € 5,194 to
11,214 Mio for the total cost or burden of illness due to
severe sepsis in Germany.
CONCLUSIONS: This study shows that the burden of ill-
ness imposed by severe sepsis in Germany is considerable.
The largest part is as a result of indirect costs due to pro-
ductivity losses, especially early retirement and premature
death. Direct costs represent about 23% of total costs.
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OBJECTIVE: As an attenuated varicella vaccine is avail-
able, the question as to whether varicella could be elimi-
nated in an acceptable time frame under cost-effective
conditions in European countries arises.
METHODS: Epidemiological data and results from mod-
eling studies conducted in France, Italy, Spain, and Ger-
many were analysed and compared. Input data for the
German decision-analytic model were mainly taken from
a seroprevalence study (4,602 sera) and a large epidemio-
logical survey (1334 cases) in 1999. For France, an epide-
miological model was developed and a prospective obser-
vational study of1832 cases was performed. The Spanish
Markov model used data from a seroprevalence study,
from hospitalizations, and from the available literature.
The Italian figures were estimated from a one-year senti-
nel network in 1997. Costs were defined as costs of the
vaccination program. Monetary benefits were defined as
direct and indirect cost savings afforded by vaccination
compared to a strategy not involving vaccination. Effec-
tiveness was measured by the number of infections
avoided.
RESULTS: The age distribution of diagnosed cases in It-
aly and Germany were similar. The complication rates in
Italy (3.5%) and France (2%) were lower than in Ger-
many (5.7%). Indirect costs were the major contributors
to disease cost and accounted for 67% of the cost in
Spain and 80% in Germany. For all countries, vaccina-
tion programs dominated the non-vaccination strategy by
saving costs for society and avoiding infections. Cost-
benefit ratios varied between 1.61 (Spain) and 4.1 (Ger-
many). The German model shows that with a coverage
rate of 85% it would be possible to eliminate varicella
within 15 years.
CONCLUSION: Indirect costs turned out to be the most
important cost factor. From an economic point of view, a
universal vaccination program is justified. The most con-
venient and cost-effective means would be the implemen-
tation of a routine vaccination program using a com-
bined measles, mumps, rubella and varicella vaccine.
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OBJECTIVES: The economic impact of flu and flu-like
illnesses (FFLIs) in Hong Kong has never been investi-
gated. Such data will facilitate the development of a cost-
effective health-care policy against the diseases. The ob-
jectives of the study include: 1) to determine the incidence
and health effects of FFLIs, and 2) to estimate the cost
